SciSparc Gains Competitive Edge with Additional U.S. Patent Granted

This patent extends safety, adding to 6 other U.S. patents currently granted

TEL AVIV, Israel, Nov. 08, 2022 (Globe NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, scientific-stage pharmaceutical enterprise focusing on the advancement of therapies to take care of diseases of the central nervous program (the “Company” or “SciSparc”), announced now that the U.S. Patent and Trademark Workplace has granted it a new patent – U.S. Patent No. 11,491,172, title: COMPOSITIONS AND Techniques OF POTENTIATING ANTIMICROBIALS (the “Patent”).

This patent even further strengthens the Company’s mental home portfolio and safety of its main systems, and in 1 of the most vital markets in the planet.

This is SciSparc’s seventh granted patent in the United States. Earlier, the Business announced it has been granted additional patents in Australia, Japan and Israel. The Company’s IP portfolio now incorporates 9 patent people and two emblems.

About SciSparc Ltd. (NASDAQ: SPRC)

SciSparc Ltd. is a specialty medical-stage pharmaceutical corporation led by an skilled group of senior executives and scientists. SciSparc’s focus is on creating and boosting a portfolio of systems and property primarily based on cannabinoid prescription drugs. With this focus, the Organization is currently engaged in the subsequent drug advancement plans based mostly on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment method of Alzheimer’s disease and agitation SCI-160 for the treatment method of ache and SCI-210 for the procedure of autism spectrum disorder and position epilepticus.

Investor Speak to:
[email protected]
Tel: +972-3-6167055

The articles is by GlobeNewswire. DKODING Media is not dependable for the material provided or any back links associated to this articles. DKODING Media is not liable for the correctness, topicality or the quality of the articles.

Leave a Reply